Acute Coronary Syndrome, Myocardial Infarction
Conditions
Keywords
clopidogrel, aspirin, percutaneous coronary intervention, coronary stenting, antiplatelet
Brief summary
This observational study will based on the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which since 2009 are merged into The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). The aim of this study is to investigate the impact of different antithrombotic treatment options (treatment duration, type of treatment and combination of treatments) in Acute Coronary Syndrome (ACS) patients on outcomes such as recurrent ischemic events and mortality.
Interventions
None listed
Sponsors
AstraZeneca
Uppsala University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patient with an event of ACS under the study period * Patient found in the National Registry of Drug Prescriptions and treated or not treated with antithrombotic drug/s (acetylsalicylic acid and/or either clopidogrel/ticlopidine/prasugrel and/or warfarin)
Exclusion criteria
* Patients will not be excluded from the database if they fulfill inclusion criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| number of patients with adverse events in patient groups with different antithrombotic treatment strategies | up to 5 years and 6 months | adverse events such as: mortality, re-infarction, revascularization, ischemic- and non-ischemic stroke and bleeding |
Countries
Sweden
Outcome results
None listed